{"id":62627,"date":"2026-04-08T20:46:44","date_gmt":"2026-04-08T12:46:44","guid":{"rendered":"https:\/\/flcube.com\/?p=62627"},"modified":"2026-04-08T20:46:46","modified_gmt":"2026-04-08T12:46:46","slug":"everest-medicines-to-acquire-eversea-medicines-singapore-for-250m-expanding-asia-pacific-chronic-disease-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62627","title":{"rendered":"Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio"},"content":{"rendered":"\n<p><strong>Everest Medicines (<a href=\"https:\/\/www.google.com\/finance\/quote\/1952:HKG\">HKG: 1952<\/a>)<\/strong> announced a definitive agreement to acquire <strong>100% of the equity interests<\/strong> of <strong>EverSea Medicines (Singapore) Pte. Ltd.<\/strong>, a subsidiary of <strong>Hasten Biopharmaceutical Co., Ltd.<\/strong> The $250 million (RMB 1.722 billion) transaction, payable in three installments, will leverage Everest&#8217;s established regional commercialization platform covering 14 marketed chronic disease products to accelerate Asia-Pacific business expansion.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Everest Medicines (HKG: 1952)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>EverSea Medicines (Singapore) Pte. Ltd.<\/td><\/tr><tr><td><strong>Parent Company<\/strong><\/td><td>Hasten Biopharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Transaction Value<\/strong><\/td><td>USD 250 million (RMB 1.722 billion)<\/td><\/tr><tr><td><strong>Payment Structure<\/strong><\/td><td>Three installment payments<\/td><\/tr><tr><td><strong>Geographic Focus<\/strong><\/td><td>Asia-Pacific region<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Accelerate business expansion through established commercial infrastructure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-assets-amp-commercial-platform\">Strategic Assets &amp; Commercial Platform<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-everest-s-existing-infrastructure\">Everest&#8217;s Existing Infrastructure<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Product Portfolio<\/strong>: 14 marketed chronic disease products across multiple therapeutic areas<\/li>\n\n\n\n<li><strong>Regional Coverage<\/strong>: Established commercial presence across key Asia-Pacific markets<\/li>\n\n\n\n<li><strong>Commercial Maturity<\/strong>: Proven track record in product launch, market access, and distribution<\/li>\n\n\n\n<li><strong>Operational Scale<\/strong>: Integrated sales, marketing, and regulatory capabilities<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-eversea-medicines-strategic-value\">EverSea Medicines Strategic Value<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Singapore Hub<\/strong>: Strategic location providing access to Southeast Asian markets<\/li>\n\n\n\n<li><strong>Regulatory Advantages<\/strong>: Singapore&#8217;s favorable biopharmaceutical regulatory environment<\/li>\n\n\n\n<li><strong>Pipeline Potential<\/strong>: Access to Hasten Biopharmaceutical&#8217;s development assets and partnerships<\/li>\n\n\n\n<li><strong>Market Entry<\/strong>: Accelerated pathway into new Asia-Pacific territories<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-structure-amp-deal-terms\">Financial Structure &amp; Deal Terms<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Consideration<\/strong>: USD 250 million (RMB 1.722 billion)<\/li>\n\n\n\n<li><strong>Payment Schedule<\/strong>: Structured across three installments to manage cash flow impact<\/li>\n\n\n\n<li><strong>Financing Strategy<\/strong>: Expected to utilize existing cash reserves and potential debt facilities<\/li>\n\n\n\n<li><strong>Accretion Timeline<\/strong>: Targeting positive earnings contribution within 12-18 months post-closing<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-asia-pacific-expansion-strategy\">Asia-Pacific Expansion Strategy<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-opportunity-assessment\">Market Opportunity Assessment<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chronic Disease Burden<\/strong>: Rising prevalence of cardiovascular, metabolic, and respiratory conditions across Asia-Pacific<\/li>\n\n\n\n<li><strong>Healthcare Infrastructure<\/strong>: Improving access to specialty pharmaceuticals in emerging markets<\/li>\n\n\n\n<li><strong>Reimbursement Evolution<\/strong>: Growing government and private insurance coverage for innovative therapies<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: Fragmented market with opportunities for integrated commercial players<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-implementation-roadmap\">Implementation Roadmap<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Integration Phase<\/strong>: 6-9 month integration of EverSea operations into Everest platform<\/li>\n\n\n\n<li><strong>Portfolio Expansion<\/strong>: Leverage existing 14-product portfolio to cross-sell into new territories<\/li>\n\n\n\n<li><strong>Regulatory Harmonization<\/strong>: Utilize Singapore regulatory approvals as gateway to ASEAN markets<\/li>\n\n\n\n<li><strong>Talent Acquisition<\/strong>: Retain key EverSea commercial and regulatory personnel<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Scale Enhancement<\/strong>: Transaction significantly expands Everest&#8217;s commercial footprint and operational scale<\/li>\n\n\n\n<li><strong>Revenue Diversification<\/strong>: Reduces concentration risk through geographic and product portfolio diversification<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: Positions Everest as a leading pan-Asia chronic disease specialist<\/li>\n\n\n\n<li><strong>Valuation Impact<\/strong>: Strategic acquisition at attractive valuation multiples relative to peer transactions<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-risk-mitigation-factors\">Risk Mitigation Factors<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Installment Structure<\/strong>: Payment terms provide downside protection and performance alignment<\/li>\n\n\n\n<li><strong>Proven Platform<\/strong>: Leverages existing successful commercial model rather than greenfield expansion<\/li>\n\n\n\n<li><strong>Regulatory Certainty<\/strong>: Singapore jurisdiction provides stable legal and regulatory framework<\/li>\n\n\n\n<li><strong>Cultural Alignment<\/strong>: Shared Asian business practices facilitate smoother integration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-context-amp-competitive-dynamics\">Industry Context &amp; Competitive Dynamics<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biopharma Consolidation<\/strong>: Reflects broader trend of regional consolidation in Asia-Pacific pharmaceutical sector<\/li>\n\n\n\n<li><strong>Chronic Disease Focus<\/strong>: Aligns with global shift toward long-term condition management versus acute care<\/li>\n\n\n\n<li><strong>Commercial Specialization<\/strong>: Validates specialized commercial platforms as competitive advantage versus large pharma<\/li>\n\n\n\n<li><strong>Cross-Border Transactions<\/strong>: Demonstrates increasing sophistication of Chinese biopharma companies in international M&amp;A<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding acquisition completion, integration timelines, and financial performance. Actual results may differ due to risks including regulatory approvals, integration challenges, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Everest Medicines (HKG: 1952) announced a definitive agreement to acquire 100% of the equity interests&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[126,4682,369,1164],"class_list":["post-62627","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-everest-medicines","tag-eversea-medicines","tag-hasten-biopharmaceutical","tag-hkg-1952"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Everest Medicines (HKG: 1952) announced a definitive agreement to acquire 100% of the equity interests of EverSea Medicines (Singapore) Pte. Ltd., a subsidiary of Hasten Biopharmaceutical Co., Ltd. The $250 million (RMB 1.722 billion) transaction, payable in three installments, will leverage Everest&#039;s established regional commercialization platform covering 14 marketed chronic disease products to accelerate Asia-Pacific business expansion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62627\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio\" \/>\n<meta property=\"og:description\" content=\"Everest Medicines (HKG: 1952) announced a definitive agreement to acquire 100% of the equity interests of EverSea Medicines (Singapore) Pte. Ltd., a subsidiary of Hasten Biopharmaceutical Co., Ltd. The $250 million (RMB 1.722 billion) transaction, payable in three installments, will leverage Everest&#039;s established regional commercialization platform covering 14 marketed chronic disease products to accelerate Asia-Pacific business expansion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62627\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T12:46:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-08T12:46:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62627#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62627\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio\",\"datePublished\":\"2026-04-08T12:46:44+00:00\",\"dateModified\":\"2026-04-08T12:46:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62627\"},\"wordCount\":520,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Everest Medicines\",\"EverSea Medicines\",\"Hasten Biopharmaceutical\",\"HKG: 1952\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62627#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62627\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62627\",\"name\":\"Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-08T12:46:44+00:00\",\"dateModified\":\"2026-04-08T12:46:46+00:00\",\"description\":\"Everest Medicines (HKG: 1952) announced a definitive agreement to acquire 100% of the equity interests of EverSea Medicines (Singapore) Pte. Ltd., a subsidiary of Hasten Biopharmaceutical Co., Ltd. The $250 million (RMB 1.722 billion) transaction, payable in three installments, will leverage Everest's established regional commercialization platform covering 14 marketed chronic disease products to accelerate Asia-Pacific business expansion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62627#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62627\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62627#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"Everest Medicines (HKG: 1952) announced a definitive agreement to acquire 100% of the equity interests of EverSea Medicines (Singapore) Pte. Ltd., a subsidiary of Hasten Biopharmaceutical Co., Ltd. The $250 million (RMB 1.722 billion) transaction, payable in three installments, will leverage Everest's established regional commercialization platform covering 14 marketed chronic disease products to accelerate Asia-Pacific business expansion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62627","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio","og_description":"Everest Medicines (HKG: 1952) announced a definitive agreement to acquire 100% of the equity interests of EverSea Medicines (Singapore) Pte. Ltd., a subsidiary of Hasten Biopharmaceutical Co., Ltd. The $250 million (RMB 1.722 billion) transaction, payable in three installments, will leverage Everest's established regional commercialization platform covering 14 marketed chronic disease products to accelerate Asia-Pacific business expansion.","og_url":"https:\/\/flcube.com\/?p=62627","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-08T12:46:44+00:00","article_modified_time":"2026-04-08T12:46:46+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62627#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62627"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio","datePublished":"2026-04-08T12:46:44+00:00","dateModified":"2026-04-08T12:46:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62627"},"wordCount":520,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Everest Medicines","EverSea Medicines","Hasten Biopharmaceutical","HKG: 1952"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62627#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62627","url":"https:\/\/flcube.com\/?p=62627","name":"Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-08T12:46:44+00:00","dateModified":"2026-04-08T12:46:46+00:00","description":"Everest Medicines (HKG: 1952) announced a definitive agreement to acquire 100% of the equity interests of EverSea Medicines (Singapore) Pte. Ltd., a subsidiary of Hasten Biopharmaceutical Co., Ltd. The $250 million (RMB 1.722 billion) transaction, payable in three installments, will leverage Everest's established regional commercialization platform covering 14 marketed chronic disease products to accelerate Asia-Pacific business expansion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62627#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62627"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62627#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62627"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62627\/revisions"}],"predecessor-version":[{"id":62628,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62627\/revisions\/62628"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}